Loading
Life sciences · Journal article
Advanced Therapeutics · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Infectious diseases are a global public health problem exacerbated by microbial resistance to the available arsenal of antimicrobials. Nanotechnology represents a viable strategy to improve antimicrobial efficacy. Lipid nanocarriers can be easily modified with specific excipients to trigger antibiotic release in response to intrinsic or extrinsic stimuli at the infection site. This scoping review aimed to assess whether stimulus‐responsive lipid nanoparticles enhance the antimicrobial activity of different active compounds. The searches were conducted on the Web of Science, Scopus, and PubMed databases. Out of 685 records, 36 were selected after applying the inclusion and exclusion criteria. Liposomes were the most widely used nanocarriers in the literature found (63.89%). The most frequently studied stimuli were pH (41.67%) and multiple stimuli (19.44%). The results demonstrated that organic or inorganic excipients can increase the efficacy of antibiotics in response to stimuli. The responsiveness conferred by such excipients was confirmed by greater in vitro release in the presence of the stimulus, as well as improved antimicrobial activity in vitro and in vivo compared with the isolated compounds. Research in this field still requires further evaluation of toxicity and pharmacokinetics in robust models before proceeding to the clinical phase.